cholinesterase inhibitors such as neostigmine, pyridostigmine or edrophonium. Antagonism performed at the correct depth of NMB accelerates the muscle recovery, [9] [10] [11] [12] [13] thereby decreasing the incidence of residual block 4 and shortening the time to full recovery.
Mivacurium is a short-acting NDMR which is hydrolyzed quickly by butyrylcholinesterase 14 (BChE, plasma cholinesterase). The rapid elimination of mivacurium ensures a clinical duration of 16.8 ± 1.1 minutes, 14 and thereby a short recovery time, why reversal with cholinesterase inhibitors may not be needed. Further, a paradox effect is seen when cholinesterase inhibitors are used for reversal of mivacurium-induced NMB. On one hand these drugs inhibit the acetylcholinesterase found at the neuromuscular junction resulting in increased acetylcholine concentration with the potential of accelerating the recovery. On the other hand a slower decrease in plasma concentration of mivacurium is seen. For neostigmine and pyridostigmine, this effect is due to inhibition of the BChE activity. [15] [16] [17] This is not the case for edrophonium. 18 The mechanism responsible of the altered decrease of mivacurium in plasma when edrophonium is administered is not known, but may be because of edrophonium displacing mivacurium from tissue into plasma. 19 The short spontaneous recovery time of mivacurium and the altered decrease in plasma concentration, when cholinesterase inhibitors are given, elicit uncertainty whether the use of cholinesterase inhibitors facilitate the reversing process or not. As cholinesterase inhibitors have adverse effects including cardiovascular effects, [20] [21] [22] the potential beneficial effect of reversal should be of significance to justify the use.
The objective of this systematic review was to assess whether the use of cholinesterase inhibitors facilitates the reversal of mivacurium-induced NMB, and further evaluate if any time difference is seen between pyridostigmine, neostigmine or edrophonium.
The hypothesis was that cholinesterase inhibitors facilitate reversal of mivacurium-induced neuromuscular block.
| METHOD S

| Protocol and registration
A protocol was published at the International prospective register of systematic reviews (PROSPERO) database, registration number CRD42016051195. 23 
| Eligibility criteria
The study population was patients receiving mivacurium. Only randomized controlled trials or crossover-studies comparing spontaneous reversal of NMB with either neostigmine, edrophonium or pyridostigmine facilitated reversal were included. The studies should report mean time of reversal measured from a specific time, assessed with quantitative neuromuscular monitoring, where either injection of the cholinesterase inhibitor was given or spontaneous recovery was allowed. The endpoint was a train-of-four (TOF) ratio of 0.9 or another level of NMB measured quantitatively representing full recovery. Studies comparing spontaneous reversal with one or more groups with cholinesterase inhibitors were included. The cholinesterase inhibitor could only be administered once, and had to be given after termination of mivacurium administration. Studies focusing on genetic variants of BChE were not included.
| Information sources
A specific search strategy was used on the databases Medline,
Embase and Cochrane Central Register of Controlled Trials (CEN-TRAL) to identify relevant studies. Also, references in the included studies were screened.
| Search
The search at Medline, Embase and CENTRAL was conducted in September 2016, and repeated in August 2018 to ensure any new publications were included (Appendix S1).
| Study selection
Titles and abstracts of the studies found were read independently by two authors (JB and CMS) to identify studies that fulfilled the eligibility criteria. Any disagreements were discussed, and in case of disagreement a senior author (MRG or MVM) was consulted. The full text of the included studies was processed in the same manner (Figure 1 ).
| Data collection process and data item
Data extraction was performed on all included studies independently by two authors (JB and CMS), using a data extraction sheet (Table S1 ) comprising study purpose, type of study, number of included subjects, dropouts, premedication, type of anaesthesia, dose of mivacurium and type of administration, as well as dose, type and administration time of cholinesterase inhibitor, time to TOF 0.9, and type of neuromuscular monitoring device. The data extraction sheets were then compared to ensure full and correct data extraction. If more than one dose was investigated in a study (eg dose-response studies), only clinically relevant doses were extracted (edrophonium ≥0.5 mg/kg, neostigmine ≥0.02 mg/kg).
Editorial Comment
In this systematic review, the authors set out to assess whether cholinesterase inhibitors accelerate reversal of mivacurium-induced neuromuscular blockade. The authors found low quality of evidence supporting this, and routine use of cholinesterase inhibitors for reversal of mivacuriuminduced neuromuscular blockade does not seem justified.
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| Risk of bias in individual studies
Checklists available from The Scottish Intercollegiate Guidelines Network (SIGN) website were used to assess the risk of bias. 24 The checklist consists of a series of questions among others description of adequate randomization, blinding, concealment of allocation, similarity of groups at the start of the trial, if the outcome is measured in a standardized and reliable way and number of dropouts. Each question could be answered with "Yes", "No", "Can´t say" or a short comment. The overall assessment of the risk of bias resulted in a grading of the quality of the individual study as High (++), Acceptable (+), Low (−) or Unacceptable (reject). The critical appraisal was done independently by two authors (JB and CMS). Discrepancy was discussed and if consensus could not be reached a senior author (MRG or MVM) was consulted.
| Summary measures, synthesis of results and risk of bias across studies
The mean times of reversal (T ± standard deviation) for the comparison group (spontaneous recovery) and the intervention group(s) (neostigmine, edrophonium or pyridostigmine) of each study were used to calculate the mean time difference of reversal (ΔT) ± confidence interval (CI) in minutes. CIs were calculated using CI = difference * t-value * standard error(diff). Standard error (SE) values were calculated using the standard deviation (SD) given in the study. If the number of dropouts was unclear, 10% dropouts was used as a standard. No CI was calculated if the result was read from a graph.
As a result of the broad eligibility criteria, it was expected to find differences in several variables (anaesthetics, doses of mivacurium, doses of cholinesterase inhibitor, time of administration) that could alter the recovery time. Accordingly, no meta-analyses were planned in the protocol. No attempt to contact study authors for additional information was done.
The first response (T 1 ) to TOF nerve stimulation was used to describe the level of NMB for administration of cholinesterase inhibitor. T 1 ≥ 5% refers to moderate NMB, while T 1 < 5% refers to deeper NMB.
Because of heterogeneity of the studies a funnel plot was not made. The overall quality assessment was done using the Grading of Recommendations Assessment, Development and Evaluation working group methodology (GRADE). 25 The quality of evidence could be rated from high to very low (see Table S2 for further description), due to evaluation of study design, risk of bias, inconsistency, indirectness, imprecision, and other considerations.
| RESULTS
The database searches resulted in 557 studies. After removal of duplicates, a total of 402 studies remained for assessment of title and abstract, which resulted in full-text assessment of 47 studies.
Thirty-one studies were excluded ( Figure 1) . Sixteen randomized controlled studies with data from 546 patients were included. 13, 15, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Six studies compared spontaneous recovery with both neostigmine and edrophonium reversal. 15, 26, 28, 30, 32, 39 Five studies compared spontaneous recovery with neostigmine reversal 31, 33, [36] [37] [38] and five studies compared spontaneous recovery with edrophonium reversal 13, 27, 29, 34, 35 No studies on pyridostigmine were included. The overall assessment of the risk of bias for individual studies resulted in three studies judged as high quality, 11 as acceptable and two as low (Table S3 ).
| Reversal with neostigmine
A total of 11 studies compared spontaneous recovery with one or more group(s) receiving neostigmine. 15, 26, 28, 30, 33, 36, 39 Study characteristics, results and quality assessment are listed in Table 1 .
The studies were heterogenic eg administration time of cholinesterase inhibitor, definition of endpoint (recovery as TOF ratio between 0.7 and 0.95), type of anaesthetics and doses of neostigmine. Two studies used our predefined endpoint TOF 0.9. 26, 36 These studies also presented time to TOF 0.7.
Reversal times after neostigmine were compared to spontaneous recovery and ranged from prolonged recovery time up to 13.5 minutes, 26 to an accelerated recovery time of maximum 7.0 minutes at T 1 ≥ 5% NMB, a tendency to accelerated reversal was seen.
| Reversal when T 1 < 5% (5 studies)
The study by Naguib 28 was divided in two parts. Two groups met our inclusion criteria, one using edrophonium, and one using neostig- In the study by Kao 26 neostigmine was administered at T 1 2%-3%. Time to TOF 0.7 was prolonged with 7.5 (−0.9; +15.9) min
[+54%] in the neostigmine group compared to the spontaneous group. At TOF 0.9 the time gap had increased to 13.5 (+3.8; +23.2)
, only the latter result was significant.
| Reversal at T 1 ≥ 5% (6 studies)
In Bartunek 30 neostigmine was administered in two groups; one group at T 1 5%, and one group at T 1 25%. In both groups, the rever- In Jan 38 all patients were given suxamethonium before intubation. When T 1 had returned to 70% of the baseline twitch, a mivacurium bolus was given followed by an infusion titrated to T 1 10%.
When infusion was stopped, neostigmine was administered or no reversal was given. Time to TOF 0.7 was similar in both groups, with the neostigmine group being 0. 
| Summary statement
There is low quality of evidence ( Table 2 ) that neostigmine administered at moderate mivacurium-induced NMB (T 1 ≥ 5%) accelerates the reversal as compared to spontaneous recovery in adults.
The effect was not clarified at deeper mivacurium-induced NMB in adults.
| Reversal with edrophonium
A total of 11 studies reported on edrophonium. Of these four studies compared different doses of edrophonium 27, 29, 32, 34 and one study compared the same dose of edrophonium given at two different levels of NMB. 30 The study characteristics varied considerably. Study characteristics, results and quality assessment are listed in Table 3 .
Two studies used the predefined endpoint TOF 0.9. 13, 26 Both studies also presented time to TOF 0.7, which was the endpoint in all other studies, apart from two trials where TOF 0.75 was used as endpoint.
28,35
The use of edrophonium accelerated the recovery of the NMB (from 1.1 minutes 28 to 9.2 minutes 27 ) compared to spontaneous recovery in all groups presented (Table 3 ).
| Reversal at T 1 < 5% (4 studies)
Naguib, 28 The inconsistency found in the results is believed to be explained for a large part by the big difference in when the cholinesterase inhibitor is administered, as well as other differences in the studies methodology. Borderline decision. The number of included patients for this outcome is less than 400 (301). Significant acceleration in reversal time is seen in half of the studies where neostigmine was administered at T 1 ≥ 5%, including the largest study. Borderline decision. Downgraded due to multiple borderline decisions. e Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. See Table S2 for explanation. f The number of included patients for this outcome is less than 400 (300). Most studies show significant acceleration in reversal time, including the largest study. Borderline decision. Downgraded due to multiple borderline decisions.
| Reversal at T 1 ≥ 5% (7 studies)
T All results regarding reversal at moderate NMB, except from Suzuki 13 and Bevan, 32 were statistically significant (Table 3) .
| Summary statement
There is low quality of evidence ( Table 2 ) that edrophonium administered at moderate and deeper mivacurium-induced NMB accelerates the reversal compared to spontaneous recovery in adults.
| DISCUSSION
This review found that neostigmine and edrophonium administered when some spontaneous recovery had occurred accelerated the recovery of mivacurium-induced NMB.
Low quality of evidence was found that neostigmine administered when T 1 ≥ 5% accelerated the reversal time with up to 6.5 minutes.
Four out of six studies showed an effect of at least 5 minutes. The effect was not clarified at deeper mivacurium-induced NMB in adults.
Low quality of evidence was found that edrophonium administered at moderate and deeper mivacurium-induced NMB accelerated the reversal time in adults with around 9 minutes. Six out of ten studies found an effect of at least 6 minutes. If administered at T 1 ≥ 5%, four out of seven studies found an effect of at least 6 minutes.
We would argue that a clinical relevant difference should be of at least 5 minutes. In this perspective, the times for reversal found in this systematic review may be of little clinical importance. However, administration of reversal agents should be based on the individual patient and type of surgery. For example, in a fast track schedule with minor surgical procedures differences of 6-9 minutes may play an important role in turn over time between cases.
The strength of our study lies in the conduction of a protocol that follows the PRISMA-P criteria in advance of conducting the study, 23 as well as the systematic approach in the methodology. A broad search strategy, including three databases was used. The outcomes and the quality assessment of included studies were extracted and assessed independently by two authors. Our broad inclusion criteria are however also a limitation as this resulted in a large variation between the different studies regarding anaesthesia method used, as well as administration of the cholinesterase inhibitor at different levels of NMB and in different doses. This heterogeneity probably explains a major part of the variability in effect found throughout the studies. For example, seven studies used inhalation agents 26, 28, 29, 33, 35, 38, 39 which is known to decrease mivacurium requirements. [40] [41] [42] Also the time for administration varied from first detection of muscle contraction in response to PTC up to T 1 = 25%.
The doses of cholinesterase inhibitor also varied. Neostigmine doses ranged from 0.02 to 0.07 mg/kg and edrophonium from 0.5 to 1 mg/ kg. Only four of the studies used TOF 0.9 or more as endpoint. The majority of the results are based on time to reach TOF 0.7-0.75.
Most of the studies were of older date, where TOF 0.9 was not recognized as the level to preclude residual NMB. 43 The three included studies which used TOF 0.9 also reported TOF 0.7. No tendency as to whether the effect became more or less pronounced could be seen when looking at TOF 0.9 instead of TOF 0.7. Another limitation is that level of NMB was not pre-specified and there is a potential risk of bias since our definitions of deeper and moderate NMB may have provided the most favourable findings. From a clinical perspective, further limitation is that the beneficial effect is not seen in relation to adverse effects of cholinesterase inhibitors combined with anticholinergics.
When comparing the two reversal agents, edrophonium seemed to be the most effective, especially when administered at T 1 < 5%.
At moderate NMB (T 1 ≥ 5%), the effect seemed more similar. The use of edrophonium accelerated the reversal with a maximum of 9.2 minutes in contrast to 6.5 minutes when using neostigmine.
Based on the study by Trévien 33 one can argue that the maximum time saved when using neostigmine should be 8.5 min instead, even though not being significant. No SD was available to this time in Trévien 33 why the largest SE listed in the study was used to calculate the CI. In the studies investigating both edrophonium and neostigmine, only small differences in accelerated reversal time were seen between the two drugs. In Bartunek 30 edrophonium was 2.3 minutes faster compared to neostigmine when administered at T 1 5%, while only 0.2 minutes difference was seen when administered at T 1 25%. In Maddineni 39 the difference was 0.2 minutes as well, while a difference of 1.6 minutes was seen in Bevan. 32 Looking at the percentage saved, the difference is minimal. The maximum percentage saved for neostigmine and edrophonium was almost identical (52%). Overall, the effect when administered at T 1 ≥ 5% was very similar.
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Beemer 10 described reversal of NMB as a function of direct antagonism produced by the cholinesterase inhibitor and spontaneous recovery, with the latter being most important at deep NMB. Neostigmine, but not edrophonium, inhibits BChE. This could be the reason that edrophonium seemed to be more effective than neostigmine at deeper NMB. Applying this theory to our results, it is possible that the direct antagonism of neostigmine overcomes the negative effect of inhibiting BChE around T 1 5%. Devcic 15 described a large variability in their results achieved when using neostigmine, with some subjects having accelerated reversal while others had a reversal time similar to that of spontaneous recovery. This variability was not seen to the same extend in the edrophonium or spontaneous groups. This variability might be explained by a variance in administration time of neostigmine around this point (T 1 1%-8%).
Regardless of type of non-depolarizing muscle relaxant, reversal is recommended in the absence of full spontaneous recovery (TOF > 0.9). 12, 44 If reversal of mivacurium-induced NMB is required, it is important to consider level of NMB along with the dose of the cholinesterase inhibitor. Also, the adverse effects of a reversal agent should be considered. These include dry mouth, cardiac arrhythmias as well as potential muscle weakness if administered when full recovery has occurred. [20] [21] [22] In conclusion, low quality of evidence was found that neostigmine and edrophonium administered when T 1 ≥ 5% accelerates the recovery time of mivacurium-induced NMB in adults with approximately 5-6.5 and 6-9.0 minutes, respectively. At deeper NMB (T < 5%) edrophonium accelerated the recovery, while the effect was not clarified for neostigmine in adults.
